South Korea's Green Cross heads for China; India's Nutraplus adding API production;

> Charles River Laboratories today announced that its contract manufacturing revenues were down in the first quarter. Release

> India's Nutraplus says it will build to API plants. Report

> South Korea's Green Cross said it intends to build a cell therapy manufacturing facility at the Guian New Area in the Guizhou province of China. Release

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.